Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $5.68 in the prior trading day, Prime Medicine Inc (NASDAQ: PRME) closed at $5.65, down -0.53%. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 3.06 million shares were traded. PRME stock price reached its highest trading level at $5.85 during the session, while it also had its lowest trading level at $5.44.
Ratios:
Our goal is to gain a better understanding of PRME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.56 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.85.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 1011704896 and an Enterprise Value of 758709184. For the stock, the TTM Price-to-Sale (P/S) ratio is 202.98 while its Price-to-Book (P/B) ratio in mrq is 12.49. Its current Enterprise Value per Revenue stands at 152.935 whereas that against EBITDA is -3.844.
Stock Price History:
The Beta on a monthly basis for PRME is 2.58, which has changed by 0.4986738 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $6.94, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 27.80%, while the 200-Day Moving Average is calculated to be 95.70%.
Shares Statistics:
The stock has traded on average 4.01M shares per day over the past 3-months and 4573090 shares per day over the last 10 days, according to various share statistics. A total of 134.49M shares are outstanding, with a floating share count of 91.65M. Insiders hold about 48.57% of the company’s shares, while institutions hold 22.12% stake in the company. Shares short for PRME as of 1759190400 were 20012461 with a Short Ratio of 4.99, compared to 1756425600 on 19248932. Therefore, it implies a Short% of Shares Outstanding of 20012461 and a Short% of Float of 18.459999999999997.
Earnings Estimates
At present, 10.0 analysts are actively evaluating the performance of Prime Medicine Inc (PRME) in the stock market.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.11 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.06 and -$1.45 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$0.87, with 9.0 analysts recommending between -$0.56 and -$1.51.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $36.12M, while the lowest revenue estimate was $2.57M, resulting in an average revenue estimate of $8.73M. In the same quarter a year ago, actual revenue was $2.98M
